Reporting owner · CIK 0001636178

Edgemond James

SEC Form 4 history for the last 180 days across 1 company, 41 transactions and 3 filings.

CFO, TRESCFO AND TREASURERUNITED THERAPEUTICS Corp
Open-market transaction mix0% buys0 buys · 35 sales

Period: Last 180 days

Trade dates in this period: May 26, 2026 – Jun 4, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings3Form 4 records
Buying$00 purchases
Selling$16.8M35 sales
Net value−$16.8MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Edgemond James transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$66.1kView disclosure →
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$713kView disclosure →
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$1.51MView disclosure →
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$565kView disclosure →
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$616kView disclosure →
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$842kView disclosure →
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$591kView disclosure →
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$239kView disclosure →
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$260kView disclosure →
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$64.8kView disclosure →
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$1.18MView disclosure →
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$130kView disclosure →
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$189kView disclosure →
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$480kView disclosure →
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$912kView disclosure →
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$529kView disclosure →
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$505kView disclosure →
UTHRUNITED THERAPEUTICS Corp
Chief Financial Officer · Treasurer
CFO, TRES
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$682kView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a sale at UNITED THERAPEUTICS Corp on Jun 4, 2026 valued at $66,057.20.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Monthly open-market activity

Last 2 reported months · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
May 2026025$0$11,385,656.88−$11,385,656.88
Jun 2026010$0$5,462,824.46−$5,462,824.46

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$481k
Median P/S size$465k
Direct41
Indirect0
Jun 4, 2026exercise

Associated companies

Counts cover all available history, including outside the summary period

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in the last 180 days

A 90-day purchase return requires an open-market buy. None is recorded in the last 180 days. Purchases filed earlier are outside the visible history and are not included.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

38 observations · May 26, 2026 – Jun 4, 2026. Window ends at the latest available report, not today.

Selected observation · Jun 4, 202618,876 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
May 26, 202628,876May 27, 2026View transaction
May 26, 202628,851May 27, 2026View transaction
May 26, 202628,716May 27, 2026View transaction
May 26, 202628,436May 27, 2026View transaction
May 26, 202628,196May 27, 2026View transaction
May 26, 202627,676May 27, 2026View transaction
May 26, 202626,636May 27, 2026View transaction
May 26, 202625,876May 27, 2026View transaction
May 26, 202625,176May 27, 2026View transaction
May 26, 202624,316May 27, 2026View transaction
May 26, 202623,876May 27, 2026View transaction
May 26, 202623,595May 27, 2026View transaction
May 26, 202622,786May 27, 2026View transaction
May 26, 202621,565May 27, 2026View transaction
May 26, 202619,636May 27, 2026View transaction
May 26, 202618,876May 27, 2026View transaction
May 28, 202628,876May 29, 2026View transaction
May 28, 202628,556May 29, 2026View transaction
May 28, 202626,595May 29, 2026View transaction
May 28, 202624,920May 29, 2026View transaction
May 28, 202623,712May 29, 2026View transaction
May 28, 202622,819May 29, 2026View transaction
May 28, 202621,885May 29, 2026View transaction
May 28, 202620,280May 29, 2026View transaction
May 28, 202619,436May 29, 2026View transaction
May 28, 202619,104May 29, 2026View transaction
May 28, 202618,876May 29, 2026View transaction
Jun 4, 202628,876Jun 5, 2026View transaction
Jun 4, 202628,756Jun 5, 2026View transaction
Jun 4, 202628,276Jun 5, 2026View transaction
Jun 4, 202627,836Jun 5, 2026View transaction
Jun 4, 202626,750Jun 5, 2026View transaction
Jun 4, 202625,205Jun 5, 2026View transaction
Jun 4, 202624,076Jun 5, 2026View transaction
Jun 4, 202623,043Jun 5, 2026View transaction
Jun 4, 202620,294Jun 5, 2026View transaction
Jun 4, 202618,996Jun 5, 2026View transaction
Jun 4, 202618,876Jun 5, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Edgemond James Insider Activity FAQ

SEC Form 4 context

Who is Edgemond James?

Edgemond James is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001636178.

Which companies has Edgemond James reported transactions for?

UNITED THERAPEUTICS Corp

When was Edgemond James's latest insider buy?

No open-market insider purchase is recorded in the last 180 days. Earlier filings are outside the visible history.

When was Edgemond James's latest insider sale?

The insider reported a sale at UNITED THERAPEUTICS Corp on Jun 4, 2026 valued at $66,057.20.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.